PubMed Health⌕ Search

Biomedical subjects

M Voss

Publications and source records attributed to M Voss.

101 records · Page 6Linked to original sources
PubMed1984

[Experiences with high-dosage short-term dithranol therapy of psoriasis].

Fifty patients with psoriasis were treated with short-term dithranol therapy. This therapy is based upon the different kinetics of penetration of dithranol in healthy and damaged skin. In inpatients once a day 1% dithranol-5% salicylic acid vaseline was applied to all parts of the skin and after 5-10 min washed off thoroughly. Within a few days the dosage was increased to 3% dithranol and the application time to 20 min if possible. The treatment was continued on an individual tolerance basis. In contrast to the in-patients, the out-patients were treated according to plan with weekly increases of dithranol concentration from 1-3% and an application time from 5-20 min. Thirty-two patients (17 in-patients, 15 out-patients) showed a good response, in 12 cases (5 in-patients, 7 out-patients) the response was fair and in 6 cases (2 in-patients, 4 out-patients) the response was poor. Short-term dithranol therapy seems to be superior to the conventional therapy with dithranol. Its advantages are the absence or insignificance of irritability of the healthy skin surrounding the psoriatic plaques, and the economy of time and expense.

Adolescent↗
PubMed1978

C-1 inactivator and cold-promoted activation of factor VII.

When exposed to temperatures between -5 degree and +5 degree C, plasma from pregnant women and from certain blood donors show shortening of the Thrombotest clotting time, kallikrein formation, and activation of blood-clotting factor VII. This phenomenon has been called cold-promoted activation of factor VII (CPA). In this study, it was found that CPA-positive plasma or serum samples which had been exposed to low temepratures showed spontaneous disappearance of C-1-inactivator activity in parallel to the shortening of the Thrombotest clotting time. C-1-inactivator antigen was not affected by storage at 4 degree C. In these CPA-possitive samples the loss of C-1-inactivator activity is caused partially by the formation of kallikrein at this temperature because when kallikrelin was added to C-1 inactivator, the latter was inactive when tested in the esterolytic assay. The formation of Hageman factor fragments may add to further loss. Purified C-1 inactivator effectively inhibited the CPA phenomenon, whereas alpha2-macroglobulin did so only weakly. This finding indicates that during exposure of CPA-positive plasma samples to low temperatures, Hageman factor fragments, which are inhibited only by C-1 inactivator, induce the activation of the kallikrein system and blood clotting factor VII. The reported lowered activity of C-1 inactivator in pregnancy is probably an artifact caused by generation of CPA during storage, since in fresh samples the levels were compeletely normal. Similarly, various subjects classified as belonging to the variant type of HANE (low C-1-inactivator activity with a normal antigen content) were found to have normal C-1-inactivator activity when determinations were made on fresh instead of frozen samples. It is recommended that plasma or serum samples should not be exposed to temperatures between -5degree and +5degree C prior to the determination of C-1-inactivator activity. Moreover, during purification procedures of kallikrein-binding antiproteases such as C-1 inactivator and also alpha2-macroglobulin, the occurrence of CPA should be avoided by the use of CPA-negative plasma as starting material.

Cold Temperature↗
PubMedDate not supplied

[The occurrence of a reovirus variant in a German broiler flock].

Broilers deriving from a parent flock, which had been effected in the 6th. month of hatching egg production, show arthritis beginning with the 12th day of life. The tarso-metatarsal joint has been affected. Birds show stunting. Body weights at slaughter and feed conversion of the affected flocks were reduced. The percentage of condemned birds before slaughter was highly increase and came up to 3-5%. Chickens of other breeder flocks, which were reared with the diseased birds, showed viral arthritis at an age of 18-20th day of life. The boilers derived from parent flocks which had been vaccinated twice during the with a 1133 reo live vaccine and before laying with an oil based vaccine of the antigen type WVU. A reovirus has been isolated (isolate K 171/87), which caused viral arthritis in 1133-immune day old chicks after parenteral and oral application. Infection of these chickens with the pathogenic reovirus of the antigen type 1133 didn't cause a disease. Also by serological examinations it was shown, that the reo-isolate K 171/87 possesses a different antigenicity. The kind of occurrence indicates, that this reovirus infection has been transmitted vertically from one parent flock and it spread laterally to chickens of other parent flocks in broiler farms.

Animals↗